Apollomics Inc., a biopharmaceutical company, has filed a prospectus related to the primary offering of 11,026,900 Class A Ordinary Shares and a secondary offering of 52,794,176 Class A Ordinary Shares, along with 432,431 Warrants to purchase Class A Ordinary Shares. This filing is part of a registration statement pursuant to Rule 424(b)(3) with Registration No. 333-278431. The prospectus details the offer and sale of shares by Apollomics as well as the sale by certain selling securityholders named within the document. The shares and warrants are related to a business combination with Maxpro Capital Acquisition Corp., a Delaware corporation. The offerings include shares issuable upon the exercise of various warrants, including Private Warrants, Extension Warrants, Public Warrants, and Penny Warrants, with exercise prices ranging from...Show More

Apollomics Inc., a biopharmaceutical company, has filed a prospectus related to the primary offering of 11,026,900 Class A Ordinary Shares and a secondary offering of 52,794,176 Class A Ordinary Shares, along with 432,431 Warrants to purchase Class A Ordinary Shares. This filing is part of a registration statement pursuant to Rule 424(b)(3) with Registration No. 333-278431. The prospectus details the offer and sale of shares by Apollomics as well as the sale by certain selling securityholders named within the document. The shares and warrants are related to a business combination with Maxpro Capital Acquisition Corp., a Delaware corporation. The offerings include shares issuable upon the exercise of various warrants, including Private Warrants, Extension Warrants, Public Warrants, and Penny Warrants, with exercise prices ranging from $0.01 to $11.50 per share. The prospectus also outlines the potential resale of these securities by the selling securityholders through public or private transactions, at market prices or negotiated prices. The completion of the Business Combination occurred on March 29, 2023, and on the same date, Apollomics completed a sale of Class B Ordinary Shares and Series A Preferred Shares to PIPE Investors for gross proceeds of $23,650,000. On May 18, 2023, all Series A Preferred Shares were converted into Class A Ordinary Shares. The prospectus further provides information on the tax implications, legal matters, and the enforceability of civil liabilities under U.S. securities laws for investors.